Evaluation of the efficacy of tripterygium wilfordii glycosides for patients with primary sjgren's syndrome

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062262

Enrollment

Unknown

Registered

2022-07-31

Start date

2022-07-30

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary sjgren's syndrome

Interventions

treatment group:Tripterygium wilfordii polyglycoside treatment

control group:Placebo orally

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Postmenopausal subjects who have no reproductive need, no gender limit; 2. Meet the 2016 ACR/EULAR classification criteria for diagnosis; 3. Accompanied by clinical manifestations of dry mouth and dry eyes; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. White blood cells less than 3.5x10 ^9/L. 2. Severe complications or liver and kidney dysfunction, interstitial pneumonia, cardiovascular and hematopoietic system complications. 3. Associated with other connective tissue diseases. 4. Mental disorders. 5. Can't cooperate. 6. Allergy to tripterygium glycosides. 7. On other medications.

Design outcomes

Primary

Measure	Time frame
serum immunoglobulin G;serum immunoglobulin M;serum immunoglobulin A;serum tumor necrosis factor -a;	—

Secondary

Measure	Time frame
natural saliva flow rate;Schirmer's test;tear break-up time;	—

Countries

China

Contacts

Public ContactJu Yanjuan

The First Affiliated Hospital of Gannan Medical College

yanjuan-ju@163.com+86 13576710502

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026